Zipprich A - Search Results

1

Prognostic indicators of survival in patients with compensated and decompensated cirrhosis.

Zipprich A, Garcia-Tsao G, Rogowski S, Fleig WE, Seufferlein T, Dollinger MM. Zipprich A, et al. Liver Int. 2012 Oct;32(9):1407-14. doi: 10.1111/j.1478-3231.2012.02830.x. Epub 2012 Jun 11. Liver Int. 2012. PMID: 22679906 Free PMC article.

2

Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.

Traussnigg S, Schattenberg JM, Demir M, Wiegand J, Geier A, Teuber G, Hofmann WP, Kremer AE, Spreda F, Kluwe J, Petersen J, Boettler T, Rainer F, Halilbasic E, Greinwald R, Pröls M, Manns MP, Fickert P, Trauner M; Austrian/German NAFLD-norUDCA study group. Traussnigg S, et al. Lancet Gastroenterol Hepatol. 2019 Oct;4(10):781-793. doi: 10.1016/S2468-1253(19)30184-0. Epub 2019 Jul 22. Lancet Gastroenterol Hepatol. 2019. PMID: 31345778 Clinical Trial.

3

Hepatic arterial flow volume and reserve in patients with cirrhosis: use of intra-arterial Doppler and adenosine infusion.

Kleber G, Steudel N, Behrmann C, Zipprich A, Hübner G, Lotterer E, Fleig WE. Kleber G, et al. Among authors: zipprich a. Gastroenterology. 1999 Apr;116(4):906-14. doi: 10.1016/s0016-5085(99)70074-0. Gastroenterology. 1999. PMID: 10092313

4

Functional significance of hepatic arterial flow reserve in patients with cirrhosis.

Zipprich A, Steudel N, Behrmann C, Meiss F, Sziegoleit U, Fleig WE, Kleber G. Zipprich A, et al. Hepatology. 2003 Feb;37(2):385-92. doi: 10.1053/jhep.2003.50065. Hepatology. 2003. PMID: 12540789

5

13C-Methacetin metabolism in patients with cirrhosis: relation to disease severity, haemoglobin content and oxygen supply.

Zipprich A, Meiss F, Steudel N, Sziegoleit U, Fleig WE, Kleber G. Zipprich A, et al. Aliment Pharmacol Ther. 2003 Jun 15;17(12):1559-62. doi: 10.1046/j.1365-2036.2003.01604.x. Aliment Pharmacol Ther. 2003. PMID: 12823160

6

Hemodynamics in the isolated cirrhotic liver.

Zipprich A. Zipprich A. J Clin Gastroenterol. 2007 Nov-Dec;41 Suppl 3:S254-8. doi: 10.1097/MCG.0b013e318150d3b5. J Clin Gastroenterol. 2007. PMID: 17975473 Review.

7

A distinct nitric oxide and adenosine A1 receptor dependent hepatic artery vasodilatatory response in the CCl-cirrhotic liver.

Zipprich A, Mehal WZ, Ripoll C, Groszmann RJ. Zipprich A, et al. Liver Int. 2010 Aug;30(7):988-94. doi: 10.1111/j.1478-3231.2010.02278.x. Epub 2010 May 24. Liver Int. 2010. PMID: 20500549 Free PMC article.

8

Incorporating indocyanin green clearance into the Model for End Stage Liver Disease (MELD-ICG) improves prognostic accuracy in intermediate to advanced cirrhosis.

Zipprich A, Kuss O, Rogowski S, Kleber G, Lotterer E, Seufferlein T, Fleig WE, Dollinger MM. Zipprich A, et al. Gut. 2010 Jul;59(7):963-8. doi: 10.1136/gut.2010.208595. Gut. 2010. PMID: 20581243

9

Comparison of balloon vs. straight catheter for the measurement of portal hypertension.

Zipprich A, Winkler M, Seufferlein T, Dollinger MM. Zipprich A, et al. Aliment Pharmacol Ther. 2010 Dec;32(11-12):1351-6. doi: 10.1111/j.1365-2036.2010.04484.x. Epub 2010 Oct 7. Aliment Pharmacol Ther. 2010. PMID: 21050237

10

Subclinical ascites defines an intermediate stage between compensated and decompensated cirrhosis.

Zipprich A, Seufferlein T, Dollinger MM. Zipprich A, et al. Z Gastroenterol. 2012 Sep;50(9):996-1001. doi: 10.1055/s-0031-1299446. Epub 2012 Sep 10. Z Gastroenterol. 2012. PMID: 22965629

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

110 results

Search Page

Filters